Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

research consortium

Empowering patients empowers results

Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials

- PMLiVE

UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval

MHRA is looking "very closely" at reports of adverse reactions to coronavirus vaccines

- PMLiVE

AZ showcases data for next-generation PARP inhibitor AZD5305

Early preclinical data presented at virtual American Association of Cancer Research meeting

- PMLiVE

Sanofi pays $160m upfront to acquire Tidal Therapeutics

French pharma company's acquisition of pre-clinical stage biotech includes mRNA-based research platform

Virtually, the same: Is it time to rethink congress strategy?

In this month’s PME, Jonathan Andrew, Technology Director at Lucid Group discusses the digital transformation that swept through the medcomms industry due to the COVID-19 pandemic. In particular, we saw...

Lucid Group Communications Limited

Advancing the Scientific Understanding of Medical Cannabis Through Real-Time User Data

David Berg, President and CTO of Strainprint, explores the current state of the medical cannabis industry in Canada and overseas and how Strainprint is bringing innovation to the industry. He...

Impetus Digital

Advancing Precision Medicine in Oncology

Jerome Madison, Host of The Precision Medicine Podcast, shares his leadership lessons and tips for building and training new sales teams in the era of precision medicine. He also dives...

Impetus Digital

- PMLiVE

New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement

Regulators in Canada and Germany have reportedly placed new restrictions on vaccine

- PMLiVE

Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine

Early-stage trial will enrol 30 healthy volunteers aged 18-40

- PMLiVE

EMA updates product information for AZ COVID-19 vaccine

PRAC reaffirms opinion that AZ vaccine's efficacy outweighs very rare likelihood of developing a blood clotting disorder

- PMLiVE

AZ publishes primary analysis for COVID-19 vaccine, showing slightly lower efficacy of 76%

AZ previously announced vaccine efficacy of 79% in US-based trial

Case studies

[CASE STUDIES] Delivering remote access to congress, symposia and enduring materials

See how three pharma companies supported the provision of virtual and on-demand scientific meetings for HCPs during COVID-19.

EPG Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links